Targeting sirtuin 1/nuclear factor erythroid 2-related factor 2/tumor necrosis factor-α pathway to modulate hepatic ischemia reperfusion-induced injury

doi:10.4254/wjh.v17.i12.110733

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 12

This Article

(45)

(51)

(0)

(13)

(1)

(683)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Hepatol. Dec 27, 2025; 17(12): 110733
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.110733

Table 2 Effect of different doses of aprepitant on alanine transaminase and aspartate transaminase in hepatic ischemia reperfusion-induced liver injury in rats

Group¹	Serum ALT levels (U/L)	Serum AST levels (U/L)
Sham	31.93 ± 1.019	195.5 ± 2.425
Sham/APRE10	24.64 ± 1.117	167.3 ± 2.013
HIR	336 ± 21.83^a^,^b	562.1 ± 34.52^a^,^b
HIR/APRE5	149.7 ± 8.767^a^,^b^,^c	476.8 ± 7.704^a^,^b^,^c
HIR/APRE10	93.24 ± 2.812^a^,^b^,^c^,^d	402.1 ± 5.717^a^,^b^,^c^,^d
HIR/APRE20	68.37 ± 1.99^a^,^b^,^c^,^d	324 ± 9.43^a^,^b^,^c^,^d^,^e

^aP < 0.05, significantly different from Sham group.

^bP < 0.05, significantly different from Sham/aprepitant 10 mg/kg (APRE10).

^cP < 0.05, significantly different from hepatic ischemia reperfusion (HIR) group.

^dP < 0.05, significantly different from HIR/aprepitant 5 mg/kg.

^eP < 0.05, significantly different from HIR/APRE10 group.

¹Values represent the mean ± SEM (n = 5-8).

APRE5: Aprepitant 5 mg/kg; APRE10: Aprepitant 10 mg/kg; APRE20: Aprepitant 20 mg/kg; HIR: Hepatic ischemia reperfusion; ALT: Alanine transaminase; AST: Aspartate transaminase.

Full Size Table

Citation: Kelleni MT, Abdelzaher WY, Adly M, Attya ME, Fawzy MA, Ibrahim MA. Targeting sirtuin 1/nuclear factor erythroid 2-related factor 2/tumor necrosis factor-α pathway to modulate hepatic ischemia reperfusion-induced injury. World J Hepatol 2025; 17(12): 110733
URL: https://www.wjgnet.com/1948-5182/full/v17/i12/110733.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i12.110733

Kelleni MT, Abdelzaher WY, Adly M, Attya ME, Fawzy MA, Ibrahim MA. Targeting sirtuin 1/nuclear factor erythroid 2-related factor 2/tumor necrosis factor-α pathway to modulate hepatic ischemia reperfusion-induced injury. World J Hepatol 2025; 17(12): 110733 [PMID: 41479522 DOI: 10.4254/wjh.v17.i12.110733]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.